# Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery

> **NCT04968366** · PHASE1 · COMPLETED · sponsor: **Beijing Tiantan Hospital** · enrollment: 11 (actual)

## Conditions studied

- Glioblastoma Multiforme of Brain

## Interventions

- **BIOLOGICAL:** Autologous dendritic cells pulsed with multiple neoantigen peptides.
- **DRUG:** Temozolomide adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT04968366
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-30
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-10-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968366, "Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04968366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*